Skip to main content

Table 3 Aggregated trial and sales data

From: Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach

 

Precision, n

Non-precision, n

p-value

Duration (years)

6.7

42

6.5

29

0.74

Enrolees

2285

40

1838

26

0.41

Total sales (m US$)

5155.8

39

8257.6

27

0.46

Drug sales/year (m US$)

607.6

39

575.0

27

0.90

R&D spend (m US$)

3530.6

42

4614.9

29

0.17

Total sales—R&D spend (m US$)

1499.5

39

3545.2

27

0.64

SEC ROI

148.9%

39

199.5%

27

0.79

SEC ROI (1997–2015)a

551.3%

14

435.1%

15

0.77

  1. m millions, n number, R&D research and development, ROI return on investment, SEC Securities and Exchange Commission
  2. aAnalysis restricted from 1997 to 2015 to allow time for drug sales to accrue
Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us